Growth through medical technology: Randox and Bosch invest heavily in the Vivalytic analysis platform
Growth through medical technology: Randox and Bosch invest heavily in the Vivalytic analysis platform
-
New partnership for Vivalytic analysis platform: Bosch and Randox
-
Laboratories Ltd. to invest 150 million euros in research, development, and
-
distribution
-
Strategic growth field: point-of-care molecular diagnostics expected to
-
become a future market worth billions
-
Growth with fully automated laboratory diagnostics: the two companies aim to
-
achieve sales in the nine-figure range by 2030.
-
Smartphone-sized laboratory: sepsis IVD grade test based on cutting-edge
-
BioMEMS technology is a joint development objective.
With many diseases, every minute counts, and determining whether a patient is presenting the symptoms of a simple cold, the flu, or something as severe as life-threatening meningitis is usually only possible after time-consuming and expensive
laboratory diagnostics. With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care ā and aims to use molecular diagnostics to become a leading provider in the
market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company. The two companies will invest around 150 million euros in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare. One goal is the development ofĀ a sepsis IVD1 grade test that will be the first to feature highly innovative and novel BioMEMS technology.
Bosch has defined medical technology as a strategic growth field. Point-of-care molecular diagnostics is expected to become a future market worth billions. And with its Vivalytic analysis platform, Bosch aims to achieve a leading position in this market. āWith cutting-edge technology from our own labs and our own production lines, we want to grow long-term together with partners in the field of precision diagnostics,ā says Stefan Hartung, chairman of the Bosch board of management. āHere, our medical technology can draw considerable benefit from our diversification, from our expertise, from the groundwork we have done in automation, miniaturization, molecular diagnostics, and from our experience in microchip development and manufacturing,ā Hartung adds. āWe are investing long-term in an exciting high-tech growth field and continuously developing it together with partners. With technology āInvented for lifeā, we can relieve the burden on medical professionals and help make the diagnose and treatment of disease fasterā.
Shared growth: decentralized diagnostics at the point of care
Bosch Healthcare Solutions and Randox are now joining forces in an attempt to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years. With Vivalytic, the two companies aim to achieve sales in the medium nine-figure range by 2030. āGlobally, healthcare is moving toward decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,ā says Marc Meier, managing director of Bosch Healthcare
Solutions GmbH. āWith our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular diagnostics PCR tests provide clarity directly at the site of sample collection,
shorten waiting times, and take the strain off the healthcare system,ā Meier adds. The two partners are a good fit: Bosch can contribute its technology and manufacturing expertise across the fields of molecular diagnostics, microchip
development and manufacturing, and miniaturization. The universal Vivalytic platform for molecular diagnostics was developed in over ten years by Bosch researchers and brought to market maturity by Bosch Healthcare Solutions. Randox has 40 years of experience in the design and development of highly sensitive IVD tests performed on a variety of technologies, including microfluidic platforms. In combination with the companyās extensive market knowledge and global sales and distribution network, this adds up to considerable opportunities for growth. āRandox has always been committed to improving health worldwide and sees the need to invest in research and development initiatives that will support clinical decision making across a variety of disease areas. Diagnostics has always been an indispensable component of healthcare, and the alignment of both science and technology makes for the perfect fit in an area for high potential impact, especially in pressure-driven environments,ā says Dr. Peter Fitzgerald, Managing Director of Randox Laboratories Ltd. Bosch Healthcare Solutions and Randox already collaborated during the Covid-19 pandemic. In spring 2020, Bosch launched one of the worldās first fully automated PCR tests for the SARS-CoV-2 coronavirus. Together with Randox, the rapid test for use in doctorās offices, nursing homes, testing stations, and hospitals was made ready for the Vivalytic analysis device within the space of just a few weeks.
Development goal: sepsis test based on BioMEMS technology
One focus of the development partnership with Randox is the implementation of a highly sensitive multiplex2test for sepsis on the Vivalytic analysis platform.Sepsis, also known as āblood poisoning,ā is a potentially life-threatening complication3 that can occur in conjunction with various infectious diseases. A medical emergency that can lead to multiple organ failure, it requires immediate medical treatment. The planned IVD grade sepsis test is to be based for the first time on the highly innovative and novel BioMEMS technology developed by teams from Bosch corporate research in Renningen and Bosch Healthcare Solutions in Waiblingen. āWe have set ourselves the ambitious goal
of adding the functions of a high-performance silicon chip based on microsystems technology to our test cartridges for the Vivalytic platform. In doing so, we will combine Boschās unique expertise in the areas of MEMS chips, molecular diagnostics, and microfluidics,ā Marc Meier says. āClinical outcomes in sepsis depend on timely diagnosis and appropriate early therapeutic intervention. Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using the highly multiplexing BioMEMS technology. Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition,ā says Dr. Peter Fitzgerald.
Smaller and faster: from microfluidics to nanofluidics ā thanks to BioMEMS
The powerful BioMEMS chip adds a further innovative analysis method to the Vivalytic test cartridge, enabling it to test simultaneously and significantly faster for a large number of different pathogens. It is called BioMEMS because it combines microelectromechanical systems (MEMS) with microfluidics for applications in the field of medical technology. In microfluidics, very small amounts of fluid in the microliter range are moved in a very small space. Miniaturization allows qualitative biochemical polymerase chain reactions (PCR) to run in parallel in real-time on a single BioMEMS chip. āCompared to previous PCR reactions, the volumes of liquids are reduced by a factor of 1,000 to the nanoliter range. The analysis of liquids is left to a small microchip,ā Marc Meier explains. With the new BioMEMS technology, fully automatic testing up to 250 genetic characteristics4 (e.g. pathogens) in one cartridge is possible in less
than 15 minutes. The test cartridge is a highly complex laboratory the size of a smartphone, so to speak. Another future advantage of BioMEMS will be simpler and faster adaptation of new tests or existing tests on the chip itself. For example, existing tests can easily be expanded to include additional features. āThe BioMEMS technology paves the way for us to move into nanofluidics, where each pathogen will be examined in a reaction vessel the thickness of a hair,ā Meier says. To achieve this, Bosch wants to create more capacity on a MEMS chip and expand it what are known as ānanocavitiesā. Thanks to t
hese very small cavities, even more biochemical processes will be able to run in parallel on a
chip. With increasing miniaturization, the technology has potential to be used in oncology as well over the long term. The BioMEMS chips are to be manufactured at the Bosch semiconductor plant in Reutlingen, with bio-integration and cartridge
assembly to be carried out at Bosch Healthcare Solutions in Waiblingen.
Vivalytic platform: easy application at the point of sample collection
The advantages of carrying out PCR tests on the Bosch Vivalytic platform lie not only in speedy a
nalysis, but also in the ease of use: Once the sample has been taken, it is placed in the test cartridge. The cartridge, which contains all the necessary reagents for the respective test, is then inserted into the Vivalytic analyser for automated evaluation. Medical staff require only brief training on how to operate it. This enables fast and targeted diagnostics directly at the point of sample collection ā either at the doctorās office or in the hospital ā without the often long and time-consuming detour via a central laboratory. Bosch Healthcare Solutions already distributes various tests for diseases of the upper and lower respiratory tract, such as SARS-CoV-2 ā also a pooling variant and as a saliva test ā or a test to differentiate between SARS-CoV-2, RSV virus and influenza. There are also tests for pathogens that cause sexually transmitted infections (STI) and MRSA / SA (āhospital germā). Starting in summer, it is planned to expand the portfolio with tests for whooping cough (Bordetella holmesii, Bordetella parapertus
sis, and Bordetella bronchiseptica), urinary tract infections (UTI), bacterial meningitis, the two most common sexually transmitted diseases (Chlamydia trachomatis; CT and Neisseria gonorrhoeae; (NG), fungal infections (Candida auris), and three tests for diarrheal diseases
(norovirus, Clostridioides difficile, HSP)
Contact persons for press inquiries:
Robert Bosch GmbH
Dƶrthe Warnk, Phone: +49 711 811-55508
E-mail: doerthe.warnk@bosch.com
Randox Laboratories Ltd.
Martin Conway, Phone: +44 (0) 28 9442 2413
E-mail: martin.conway@randox.com
Randox announce ‘Race Against Dementia’ as partner charity for Randox Grand National Festival 2024.
Race Against Dementia is announced as partner charity for Randox Grand National Festival 2024. The charity was founded by three-times Formula One World Champion, Sir Jackie Stewart, OBE, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
Race Against Dementia is announced as partner charity for Randox Grand National Festival 2024. This will be their second consecutive year as partner charity. Founded by three-times Formula One World Champion, Sir Jackie Stewart OBE, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
Race Against Dementia’s vision is to one day win the race against dementia by accelerating global research towards a breakthrough cure. Together we can beat dementia – faster. Currently more than 55 million people are affected by dementia worldwide. Sadly, unless something changes, 1 in 3 people born today will die with dementia.
Dementia affects different parts of the brain; some people with dementia may have trouble remembering things, while others may have trouble with language or performing tasks they used to do easily. There are many types of dementia. Each one can affect people differently, causing problems with memory, thinking and behaviour. There is unfortunately, no cure currently for this progressive disease.
As pioneers of prevention and 4-year principal partner of the Randox Grand National, Randox is proud to spread awareness of the power of preventative testing which can identify fences to clear in your health early and make you a front runner for a healthier future. As a global diagnostics company, with over 40 years of experience and a focus on preventative healthcare, Randox and Race Against Dementia are natural partners.
Throughout the three-day festival at Aintree, the charity partner will be supported to highlight the impact of the disease and to raise funds for much needed research into its prevention and cure. On Ladies Day (Friday 12th April), Randox’s sponsored race over the Grand National Fences will be titled ‘The Randox Supports Race Against Dementia Topham Chase’, with opportunities to reach out to both the racing public, and through the festival’s media coverage, to the nation.
In the pursuit of a cure for dementia, improved testing and diagnosis will both enhance patient management and greatly accelerate the race for treatment. In the last 12 months, Randox have processed over 5 million tests from health-conscious clients across the UK & Ireland, through our accessible and comprehensive in-clinic and at-home testing services.
Randox provides access to unrivalled insights that allow you to take control of your health, empowering you to makeĀ simple lifestyle changes that could help protect future illness. Also offering specific tests across key health areas including sexual health, hormonal health, digestive, and a range of genetic and other health testing both at-home and in-clinic, at one of our health clinics located throughout the UK and now in selected John Lewis stores – providing easy access for millions of people to a new range of preventative health packages designed to help clients take control of their health.
Sir Jackie Stewart OBE, Founder of Race Against Dementia: “The Randox Grand National is truly a highlight in the sporting calendar. We, at Race Against Dementia are very grateful to Randox Laboratories for supporting us once again this year. Someone is diagnoses with dementia every three seconds and together, through raising funds and awareness, we can accelerate progress towards finding both a prevention and a cure for dementia.
Dr. Peter FitzGerald, Managing Director of Randox: “We are once again proud to partner with Race Against Dementia as our nominated charity for the Randox Grand National Festival 2024 – Race Against Dementia is a cause very close to our hearts!
“As a global diagnostics company, with over 40 years of experience and a focus on preventative healthcare, Randox and Race Against Dementia are natural partners.”
For more information please visit: raceagainstdementia.com/what-is-dementia/Ā
The Randox Grand National Trophy (2024) is revealed.
Friday, 29th MarchĀ
The Randox Grand National Trophy is one of the most iconic and prestigious sporting trophies in the world of horseracing.
From the start of the Randox sponsorship in 2017, Randox CEO Dr. Peter FitzGerald proposed a unique trophy would be designed and produced each year – the winning owner receiving a full-sized trophy, with the winning trainer, jockey and groom all receiving a miniature version.Ā
Each trophy is uniquely Randox and has a story to tell. The design on the trophy has evolved over the years. Innovation is a characteristic that Randox takes great pride in. Randox is dedicated to improving health using innovative diagnostic technologies. This year’s design was the innovative work of talented De Montfort University placement student, Ritik Tailor.Ā
On his design, Ritik says, “I am very fortunate to be given the opportunity to design the Randox Grand National Trophy. Being entrusted with such an important design at the start of my placement is quite rewarding. With the support of the team, I was able to create a trophy that feels like a major accomplishment for me as an intern. It’s also an incredible opportunity as the trophy is being presented to the winning jockey at the Randox Grand National. It is a great feeling that something I have created will be woven into the history of such a prestigious sporting event.”
This year’s trophy has two key elements -the design showcases the elegance of a horse mid-jump with nods to Randoxās expertise in biochemistry. A double helix, representing DNA, rises from the base of the trophy and is partially encased by two silver rods that act as its handles.
The horse, rising from a circular blood drop – is one of the most iconic symbols of the event, was something Ritik considered an essential component to incorporate into the design. “I wanted to capture the racehorse in a way that would make it stand out as the focal point of the trophy.” adds Ritik, “After brainstorming a couple of sketched, I decided on a dynamic and lifelike horse sculpture.”
But the life-like horse sculpture is not the only element that makes the trophy unique.
The Randox iconic logo is incorporated into the base in a subtle, yet impactful way – perfectly complimenting the horse. To tie everything together the DNA Helix design is another key feature.
“I wanted to incorporate Randox’s expertise in the field of biochemistry and molecular diagnostics into the design. This intricate design is etched into the metal base of the horse, symbolizing Randox’s icon.”
Graphic Design Team Lead, Elizabeth Heaney adds, “Ritik has truly made his mark within our design team during his placement. His trophy design being chosen over others from multiple designers is a testament to his creativity and talent. We couldn’t be prouder of this years Randox Grand National trophy – and I hope Ritik feels the same sense of accomplishment for his involvement in its creation.
“It’s amazing to think that Ritik accomplished this feat within just four weeks of joining Randox, demonstrating his quick adaption to the company and his ability to create a design that embodies Randox’s essence flawlessly!”
The Randox Grand National trophies over the years have been brought to life by silversmith, Cara Murphy who adds, “This is the fifth year I have had the honour of making the Randox Grand National trophy. It is always exciting to see the different designs and how they each celebrate the event.”
Overall, the Randox Grand National Trophy isĀ beautiful and intricate work of art that embodies the company’s commitment to innovation, accuracy, and precision in the field of diagnostic testing and opportunity.
Randox Health announce partnership with Simplyhealth
Simplyhealth is now offering customers of its Health Plan discounted access to 10 Randox Health home testing kits able to detect common lifestyle related conditions including high cholesterol, vitamin deficiencies or diabetes.
24.4% of the UK population were at risk of at least one underlying health condition in 2019*. Reports from Randox Health home test kits will enable members to act early by suggesting simple lifestyle changes or directing them to a GP for further advice and guidance.
Simplyhealth Health Plan members can purchase discounted tests via the SimplyPlan app or the online Simplyhealth portal, under the SimplyRewards section. Members can choose from 10 Randox Health home test kits that measure up to twenty-four biomarkers related to heart, kidney, liver, iron, diabetes, thyroid, and nutritional health, providing fast, accurate, and convenient insights into their health.
The ten discounted at home test kits are: Vitamin D, Vitamin B12, Heart Health, Thyroid Health, General Health, Male Hormones, Female Hormones, STI, Anti-mullerian hormone (AMH), and Prostate-specific Antigen (PSA). Full details of each test can be found on the Simplyhealth and Randox websites.
David Ferguson, Chief Operations Officer for Randox Health said:Ā “We are pleased to announce this partnership with Simplyhealth, providing their members with discounted Randox Health home testing kits.
“Our range of specialised health packages enable you to take control of your health, using our innovative diagnostic technologies which can give a comprehensive overview of an individual’s health, helping to detect the earliest signs of illness. Together we can work towards preventative healthcare.”
Claudia Nicholls, Chief Customer Officer for Simplyhealth said āA better understanding of the body can empower people to make diet and lifestyle changes that could help prevent future illness. We are passionate about making healthcare more accessible to all and our partnership with Randox Health is just one of the ways we are helping people to take more control of their health and prevent them from becoming ill.
Simplyhealthās Health Plan for businesses can be tailored to meet the specific needs of any workforce and is available for under Ā£5 per employee, per month, making it more accessible and easier to offer the entire workforce cover. Individuals can access the service as part of Simplyhealthās 1-2-3 Health Plan from just Ā£20 a month.
New UK-developed test can help predict who will develop type 1 diabetes and unlock treatment
- New drugs are emerging for type 1 diabetes (T1D), but they can only be given before a person has a clinical diagnosis
- Now countries across the world are looking at introducing the first global screening programmes to identify who is at high risk of developing the disease, to prescribe before it is too late
- A new biochip by Randox, developed with the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing T1D, filtering who should go forward for further testing and accelerating access to treatment where needed.
A new test that uses genetics to help predict who is at high risk of developing type 1 diabetes is now publicly available for the first time, following research that aims to help people across the globe access new drugs that can modify the disease.
The test could help develop new screening programmes for type 1 diabetes, as new drugs emerge which must be prescribed at early stages to be effective. The new test will also help determine type 1 from type 2 diabetes, further improving clinical decision making and treatment.
The test, developed by UK diagnostics company Randox using research from the University of Exeter, could help introduce public health screening in the UK and across the world, supporting those with a high genetic risk of developing type 1 diabetes. Now, the test has received UK regulatory approval ā the first such approval issued globally. This means it will be available to consumers in the UK, through Randox Health clinics, and can be ordered online for sample collection at home and returned to Randoxās laboratories for testing.
Type 1 diabetes has a significant inherited risk. The new test is conducted on a Randox biochip which can simultaneously identify up to 10 genetic variants linked to risk for type 1 diabetes. An algorithm is then applied to assess the risk associated with the identified variants for each individual, to calculate a genetic risk score. Previous trials have shown that genetic risk scores are particularly effective in predicting risk for type 1 diabetes. This score will help identify people who donāt have diabetes but are at high risk of developing the disease in the future and can be referred for autoantibody testing to give a definitive diagnosis. The Randox biochip can also be used after diagnosis, to help identify what type of diabetes a person has, which is crucial to ensuring they get the best possible treatment and care.
Identifying those at high risk is particularly topical, as new drugs emerge that can reduce the impact of type 1 diabetes ā and they can only be given at the earliest stages, before a clinical diagnosis is given. In November 2022, the US Food and Drug Administration (FDA) approved the use of teplizumab ā the first disease-modifying treatment for type 1 diabetes. It can only be prescribed pre diagnosis, yet there is currently no screening programme anywhere in the world to identify early pre-clinical type 1 diabetes. The drug is not yet approved for use in the UK, however, health services globally are now considering how best to introduce public health screening programmes. Diabetes clinician Professor Richard Oram, of the University of Exeter, developed the genetic risk score based on a decade of research, and has worked with Randox on developing the new biochip. He said: āThe world is waking up to the value of screening programmes for type 1 diabetes because of new drugs which must be given at the earliest stages of disease. Our new biochip is a pioneering example of how understanding a personās background genetic risk can help identify those at highest risk, ensuring they have further antibody screening so we can efficiently identify type 1 diabetes early enough for treatment to be effective. The Randox biochip could aid in speeding up decisions
around who should be monitored and tested further, making public health screening cost effective and improving lives by increasing access to treatment.ā
Type 1 diabetes affects more than eight million people worldwide, and numbers are projected to rise significantly. The disease causes the bodyās own immune system to attack the beta cells which regulate blood sugar. Although the disease is primarily caused by genetics, only around one in ten people with type 1 diabetes have a family member affected, making the other nine in ten difficult to identify. Currently, they are often referred for autoantibody tests when symptoms start to show ā but that can be too late to mean they are eligible for treatment.
The new fingernail-sized biochip works by applying DNA extracted from a patientās blood sample to the biochip surface, upon which copies of the high-risk type 1 diabetes genetic variants are fixed. If a match occurs, the patientās DNA will bind to the fixed risk variants and emit light. The pattern of positive genetic variants indicates genetic risk and an algorithm is then applied, factoring the significance of each gene variant. The higher the genetic score, the greater the risk that the individual will develop the disease. Those at high risk can then be monitored and put forward for autoantibody screening, while those at low risk need not be screened, which saves money.
Dr Lucy Chambers, Head of Research Communications at Diabetes UK, said: āWeāre delighted to see that research supported by Diabetes UK has informed the development of an innovative new tool to find people at high risk of type 1 diabetes. New treatments to prevent or delay type 1 are on the horizon, and their success hinges on establishing effective screening methods to pinpoint those at higher risk. We are continuing to fund research into type 1 screening and are pleased to see new innovations that have the potential to improve lives.ā
Hilary Nathan, Director of Policy and Communications at JDRF UK: āFor too long, type 1 diabetes has lain silent and undetected to subsequently devastate lives and cause chaos from the first days of diagnosis. This new biochip from Randox and the University of Exeter is exciting, as the test could provide a new way to predict who is at risk from developing type 1. This knowledge then unlocks the opportunity to provide education and intervene at the earliest stages, enabling us to reduce the number of people being diagnosed with diabetic ketoacidosis, which can have traumatic and potentially fatal consequences. We are also on the cusp of a wave of transformative treatments, which can delay the onset of type 1, offering people invaluable years of life free from its burdens.”
Dr Peter FitzGerald MD of Randox said: āWeāre delighted to have worked with the University of Exeter on this project to provide a screening tool to assess the genetic risk of type 1 diabetes which, aligned with autoantibody testing, can greatly improve diagnosis, patient care and access to therapeutics. As a result of our regulatory UKCA approval we will, as a world first, be providing this test through our Randox Health clinics, including within certain John Lewis stores, to private individuals in the UK from7th March. We are also releasing the test via a home-based sample self-collection kit. This test is a game-changer in the diagnosis and treatment of type 1 diabetes and we look forward to deploying the test to support public and private healthcare providers globally.”
The benefits of understanding your health status
Randox Health believe in takin a proactive approach to health – making it their mission to deliver accurate and informative preventative health directly to consumers, all the while helping to relieve some of the strain felt by the health service.
More than 4.3 million people in the UK now live with diabetes. Additionally 850,000 people could be living with diabetes who are yet to be diagnoses. (Diabetes UK)
The Office for National Statistics also estimated that one in nine adults – equating to more than five million people – have non-diabetic hyperglycemia, or ‘pre-diabetes’. Making it one of the most common conditions that people live with – most people with diabetes, with the right medication and management, can live completely unencumbered lives and new technologies are making it even simpler. However, if the right care is not provided, diabetes can increase your risk of several serious complications.
Journalist, Matt Rudd, with a group of colleagues from The Times, UK, recently undertook the Randox Health Vital test – which allows you to understand your health baseline by reviewing vital health areas that could increase your risk of heart attack, stroke, and Type 2 diabetes.
Matt described the test as ‘making sense’, “…even though most cases (of type 2 diabetes) are linked to poor diet and obesity those people in the undiagnosed category are likely to be slimmer, younger and in good general health.”
Understanding your health data is vital in helping you to not only feel your best but can also help to prevent illness and reduce your risk of common conditions. The Randox Health Vital health check provides insight into four essential health areas and provides key data empowering you to take control of your health:
- Personal measurements including blood pressure and body composition are measured, If left unmanaged, high blood pressure can increase your risk of heart attack or stroke.
- Heart Health – find out if your levels of both good cholesterol (HDL cholesterol, triglycerides and total cholesterol/ HDL Ratio – higher than normal levels of LDL cholesterol may make you more likely to have heart problems or stroke.)
- Diabetes Health – HbA1c levels are measured to provide an overall picture of average blood sugar levels over a period of weeks/ months. HbA1c levels can be used to indicate prediabetes or diabetes.
- Full blood count.
The easy-to-interpret report from this Health test will provide a breakdown of results, what they mean and next steps.
By finding out if you are at increased risk of conditions such as those that the Vital package tests for, you can choose to make lifestyle changes to help improve your risk of these potentially devastating conditions.
Medical director for Randox Health, Dr. Gary Smyth provided the following comments for the Times article.
“I believe we should be screening more widely. As the adage goes, prevention is better than a cure. We’re not talking about eradicating type 2 diabetes, but we know it’s am entirely preventable disease with the correct lifestyle choices. It’s depression that there isn’t a system to test more people at a younger age.”
To read the full Times article: https://www.thetimes.co.uk/article/35d441ef-49fa-4b1a-978b-13792123cde9?shareToken=6f1dbe1f2bf3e591663f0c240d92c9ae
John Lewis offering in-store blood tests that could help drive down NHS waiting lists.
Retail giant John Lewis is to offer customers in-store blood tests in an unprecedented rollout across stores that could help drive down NHS waiting lists. The company has partnered with diagnostics firm Randox in a novel programme which will offer customers health checks, including those for certain cancers, diabetes and heart disease.
It is believed to be the first time blood tests are offered in department stores and follows the success of a pilot scheme last winter.
The news comes as Randox launches a suite of new blood tests which it says can pick up markers for some cancers at an early stage.
Randox has been in talks with senior NHS officials urging them to adopt its pioneering technology that identify abnormalities using a special microchip.
It believes its novel ālab on a chipā tests for prostate, bladder and gastrointestinal cancers could cut the NHS waiting list by reducing the number of patients having to undergo invasive and sometimes painful diagnostic tests. This could include cystoscopies – the procedure that King Charles was likely to have undergone as part of investigations into his prostate condition.
NHS officials have been given data showing up to 2.2 million people could be lifted off the waiting list and Ā£3 billion a year saved if the Randox blood cancer tests were routinely used in the NHS. Ministers are said to be examining the findings.
Checks for vitamin and mineral deficiencies, fertility and hormonal health as well as genetic testing for disease are also being offered.
Blood samples are sent to labs and results are sent back to clients who are able to book post-report consultations.
Naomi Simcock, Executive Director, John Lewis, said customers are āincreasingly seeking personalised, preventative health and wellbeing care.ā
She added: āOur stores can play an important role by making vital services like healthcare more convenient and accessible.ā
Dr Peter FitzGerald, Managing Director of Randox Health said: āOur comprehensive testing packages provide the foundation for individuals to take greater control of their health and optimise the potential to live well for longer. Randoxās presence in John Lewis stores will increasingly improve accessibility to leading healthcare prevention and wellbeing.”
A government spokesman said: āWe have already made available Ā£2.3 billion in capital investment over three years to transform diagnostic services, including improving digital diagnostic capabilities, and we have opened 153 community diagnostic centres, delivering more than six million additional scans to date.
āThe NHS carefully considers any treatment or procedure proven to improve or speed up diagnosis.”
Words by Lucy Johnston, Health and Social Affairs Editor of the Sunday ExpressĀ
King Charlesā recent cancer diagnosis highlights the importance of early detection.
King Charles’ recent cancer diagnosis has highlighted the importance of early detection. By detecting potential health issues early at Randox Health, individuals can implement lifestyle changes, treatment plans, or preventative measures that might help mitigate or event prevent the progression of certain diseases.
At Randox Health, we deliver the information to empower people to be proactive about improving their health and well-being.
Using novel biomarker-based algorithms, Randox Health deliver real-time information on cancer risk e.g., prostate cancer and bladder cancer, allowing earlier intervention and treatment.
Traditionally, prostate cancer risk assessment involves PSA testing. PSA measures the level of Prostate Specific Antigen in the blood and can indicate abnormality within the prostate.
Although PSA is highly specific for prostate disease, it is not specific for prostate cancer. A raised PSA can also indicate an enlarged prostate, prostatitis, or a urinary tract infection.
The new Randox Health Prostate Cancer Risk algorithm combines traditional PSA testing, with analysis of novel biomarkers to help determine risk of prostate cancer. Combining biomarkers in this way can help strengthen assessment and enable those with an increased risk of prostate cancer to be prioritized for further investigation, as well as reducing the need for unnecessary and invasive further investigations in low-risk individuals.
It is estimated that 30-50% of all cancer cases are avoidable, in many cases early detection is key and can save lives – cancer that is diagnosed at an early stage, when it isn’t too large and hasn’t spread, is more likely to be treated successfully.
Spotting cancer at an early stage saves lives, many people however, don’t have access to the information or services to facilitate this detection – Over 8 million people within the UK are currently awaiting diagnostic testing. At Randox Health, with over forty years’ experience in creating new and innovative diagnostic technologies, we have a focus on early diagnosis and prevention; aiming to achieve better health outcomes whilst reducing the burden on clinical services.
At Randox Health we offer genetic risk tests for inherited cancers including Breast and Ovarian Cancer, Bowel Cancer, and others. In addition, we offer a range of full body health checks that include common tumour associated markers.
The results gained allows you to not only get a more accurate interpretation of your current health status but knowingly make lifestyle changes that can help you prevent future health risks.
Additional Information on tests available at Randox Health
Genetic Cancer Risk
Available from £750
1 in 10 cancers are thought to be caused by hereditary gene mutations. Our Genetic Cancer Risk test covers 94 different genes suspected to play a role in predisposing one to cancer, including genes associated with increased risk of breast, ovarian, prostate, colorectal and thyroid cancer.
If a genetic variant linked to cancer is found there are options available to help reduce the risk of developing cancer.
- Lifestyle changes
- Regular screening and health checks
- In some cases – risk-reducing surgery.
Our Randox Health Genetic Counsellor will guide and support you throughout testing processes and will also be available to explain your results and advise on next steps.
Genetic Breast and Ovarian Cancer Risk
Available from £499.
Around 5-10% of breast cancer cases are thought to be hereditary and up to 20% of ovarian cancers are genetic. Our Genetic Breast and Ovarian Cancer Risk test covers 8 different genes including BRCA1 and BRCA2 associated with both hereditary breast and ovarian cancer.
Genetic Bowel Cancer Risk
Available from £499
It is estimated that 1 in 15 males and 1 in 8 females will develop bowel cancer in their lifetime with around 5-10% of all bowel cancers thought to be caused by a mutation in a known gene. Our bowel cancer risk test screens for mutations in 11 different genes associated with increased risk of bowel cancer.
Advanced PSA
Available from £49
Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on PSA levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.
Using a novel combination of biomarkers including PSA, our prostate Cancer Risk Score can help to assess your risk of prostate cancer and help reduce the need for unnecessary, invasive further investigations in low-risk individuals.
A recent study demonstrated that the combination of markers included within this test significantly improved the predictive potential of PSA alone in identifying individuals with prostate cancer.
Everyman/ Everywoman Plus Tumour-Associated Markers
Available from £857
With this health package you can get unrivalled insights on your overall health in addition to several tumour markers associated with bowel, ovarian, prostate, liver, and pancreatic cancer from a simple blood test. Regular health screenings helps to identify risks early allowing you to get the appropriate treatment sooner.
Signature Platinum Range
Available from £2600
Get truly unrivalled insights on your current health and future health risks that empower you to take action to help improve your health and prevent illness.
Measure 350 health data points relating to your full body health including genetic, stress, neurological & tumour associated markers with full repeat testing after 6 months is included to allow you to effectively evaluate the progress of your health journey to the fullest and identify further areas for improvement.
GPs appointments, referrals and prescriptions are included if required.
Free NHS Health Check Service for Doncaster Residents in partnership with Randox Health
From February 5th, eligible Doncaster residents aged between 40-70 will be able to book a free NHS health check.
The health checks aim to detect the risk of an individual having a heart attack, stroke, or developing Type 2 diabetes over the next decade. In its first five years, the NHS Health Check initiative is estimated to have prevented over 2,500 heart attacks or strokes as a result of people receiving preventative treatment following their Health Check.
Following the Health Check, the results will be made available to GP’s for inclusion on patient medical records to enable further follow-up if required. Not only does the Health Check enable prevention and mitigation through the early identification of serious illness, but it also offers onward support if required to assist with lifestyle modification on issues including smoking, alcohol, and weight management.
This service is specifically focussed on providing checks to patients at high risk, therefore selected patients will receive a letter on behalf of their GP inviting them to avail of the check. The dedicated NHS Health Check Clinic t Cussins House, 22-28 Wood Street is situated conveniently in central Doncaster benefitting from excellent accessibility and transport links. In addition to this, for those that cannot access the city centre, appointments will be provided at a range of community locations across the borough.
To check your eligibility and book an appointment please visit: NHS health Checks (randox.com)
or phone the Randox team on: 0800 2545 452
David Ferguson, Chief Operating Officer for Randox Health, said: “At Randox Health we promote preventative healthcare and action, so are delighted to be part of this initiative to bring health checks to Doncaster.
“We believe that early diagnostic health testing delivers better outcomes for individuals, relieving the pressure on our NHS by enabling lifestyle changes and medical intervention.”
Additional notes:
- To be eligible patients must be aged between 40 and 74, live or be registered to a GP in Doncaster, and meet the criteria regarding previous conditions.
- NHS Health Check Doncaster Address: Suite 1-05 & 1-06 Cussins House, 22-28 Wood Street, Doncaster, DN1 3LW.
- Appointments must be booked in advance and will be available from Wednesday, 14th February.
Free health checks in Sandwell
Sandwell residents will be able to benefit from diagnostic NHS Health Checks, testing for diabetes, heart and kidney disease, and hyper tension.
After the launch of Sandwell Council’s partnership with Randox Health in 2023,which saw thousands of eligible Sandwell residents offered diagnostic NHS Health Checks, the partnership has continued – giving residents a health boost for 2024!
Free tests will be offered to Sandwell residents aged between 40 and 70 who have not previously suffered coronary heart disease, strokes, diabetes, or kidney disease. Over the next few weeks those eligible will receive letter inviting them to the 20-minute NHS Health Check, under joint branding from Randox, Healthy Sandwell and the NHS.
Tests and clinics will be available for Sandwell residents in both Sandwell and, if convenient, in Birmingham, with additional free body composition analysis for health checks completed at the Birmingham clinic. Results will be made available for GPs for review and inclusion on patient medical records.
Not only does the testing programme enable prevention and mitigation through he early identification of serious illness, but it also allows lifestyle modification on issues including smoking, alcohol, and weight management. This partnership also includes a limited number of 3-month free gym memberships.
Councillor Suzanne Hartwell, Sandwell Council’s Cabinet Member for Adults, Social Care & Health, said: “The good health of our residents has always been a priority for the Council. This initiative will have a significant and beneficial impact on the health and longevity of thousands of people living in the area. It will enable those at high risk to take medical and lifestyle steps to prevent illnesses which could, if not detected early, shorten, or change lives.”
David Ferguson, Chief Operating Officer for Randox Health said, “Randox is delighted to be part of this joint initiative with Sandwell Council’s Public Health Team. It has long been our belief that early diagnostic health testing delivers better outcomes for individuals. It relieves the pressure on our NHS by enabling lifestyle change and medical intervention. This in turn, prevents or mitigates illnesses which could otherwise require intense long-term treatment.”